In 100 adults with isolated severe TBI in Cape Town, antisecretory factor (Salovum) via nasogastric tube vs placebo lowered 30-day mortality (20% vs 39%; RR 0.52, 95% CI 0.271–0.997). Therapy intensity and ICP were similar; no significant adverse events.
RCTn = 100
Cederberg et al. Salovum® reduces mortality in isolated severe traumatic brain injury: a randomized phase II trial